Shawn Shambaugh, M.D.
NPI 1659360253 · Specialist · Bakersfield, CA
Enrolled with Medicare as Practitioner - Hematology/Oncology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1659360253
- Entity type
- Individual
- Primary specialty
- SpecialistOther Service Providers
- Credential
- M.D.
- Sex
- Male
- Sole proprietor
- No
- License
- A52158 (CA)
Specialties & taxonomies
Other Service Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
36,391 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Complete Blood Cell Count (red Cells, White Blood Cell, Platelets), Automated Test and Automated Differential White Blood Cell Count85025 | 3,599 | $8 |
| Blood Test, Comprehensive Group of Blood Chemicals80053 | 3,288 | $10 |
| Uric Acid Level, Blood84550 | 3,264 | $4 |
| Lactate Dehydrogenase (enzyme) Level83615 | 3,263 | $6 |
| Insertion of Needle Into Vein for Collection of Blood Sample36415 | 3,066 | $9 |
| Magnesium Level83735 | 2,946 | $7 |
| Ferritin (blood Protein) Level |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 19 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Letrozole | 130 | 22 |
| Ibrutinibbrand: Imbruvica | 57 | — |
| Enzalutamidebrand: Xtandi | 48 | — |
| Lenalidomidebrand: Revlimid | 38 | — |
| Hydroxyurea | 36 | — |
| Anastrozole | 30 | — |
| Tamoxifen Citrate | 29 | — |
| Bicalutamide | 27 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$6,160 across 269 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2005-10-17
- Last updated
- 2010-10-05
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.